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Abstract
Background: The use of mechanical ventilation is associated with lung injury in preterm infants and therefore the
goal is to avoid or minimize its use. To date there is very little consensus on what is considered the “best non-
invasive ventilation mode” to be used post-extubation. The objective of this study was to compare the
effectiveness of biphasic nasal continuous positive airway pressure (BP-NCPAP) vs. NCPAP in facilitating sustained
extubation in infants ≤ 1,250 grams.
Methods: We performed a randomized controlled trial of BP-NCPAP vs. NCPAP in infants ≤ 1,250 grams extubated
for the first time following mechanical ventilation since birth. Infants were extubated using preset criteria or at the
discretion of the attending neonatologist. The primary outcome was the incidence of sustained extubation for 7
days. Secondary outcomes included incidence of adverse events and short-term neonatal outcomes.
Results: Sixty-seven infants received BP-NCPAP and 69 NCPAP. Baseline characteristics were similar between
groups. The trial was stopped early due to increased use of non-invasive ventilation from birth, falling short of our
calculated sample size of 141 infants per group. The incidence of sustained extubation was not statistically different
between the BP-NCPAP vs. NCPAP group (67% vs. 58%, P = 0.27). The incidence of adverse events and short-term
neonatal outcomes were similar between the two groups (P > 0.05) except for retinopathy of prematurity which
was noted to be higher (P = 0.02) in the BP-NCPAP group.
Conclusions: Biphasic NCPAP may be used to assist in weaning from mechanical ventilation. The effectiveness and
safety of BP-NCPAP compared to NCPAP needs to be confirmed in a large multi-center trial as our study
conclusions are limited by inadequate sample size.
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Background
With advances in neonatal care, > 85% of infants with
birth weight < 1,500 grams now survive [1,2]. Parallel to
this improved survival is the increase in the incidence of
bronchopulmonary dysplasia (BPD). In 2001, the National
Institute of Child Health and Human Development Neo-
natal Research Network reported an incidence of BPD of
up to 40% in infants < 1,000 grams [1] while the incidence
of BPD was reported to be 21.4% (inter-quartile range
12.5%, 30.6%) for infants born between 501-1,500 grams
in 750 neonatal intensive care units (NICUs) participating
in the Vermont Oxford Network for the year 2008 [3].
Similarly in Europe, the incidence of BPD was 19.6% for
the year 2006 among 60 NICUs participating in the
EuroNeoNet [4]. Recently in 2010, Finer et al reported the
incidence of BPD to be as high as 44% for infants born
between 240/7 to 276/7 weeks gestation [5].
Bronchopulmonary dysplasia is a multi-factorial condi-
tion with interplay of antenatal, genetic and environmental
factors. Central to its pathogenesis are lung immaturity
and the use of mechanical ventilation [6]. It has been
hypothesized that earlier extubation and use of nasal con-
tinuous positive airway pressure (NCPAP) may decrease
lung inflammation and reduce the incidence of BPD [7]. It
may also reduce ventilator-associated pneumonia and
necrotizing tracheitis. Further, baboon studies suggest that
the early use of CPAP may mitigate the decreased brain
growth and cerebral neuropathologies seen in preterm
infants who require ventilation [8]. Supporting evidence in
human neonates comes from the results of the caffeine for
apnea of prematurity trial where the investigators demon-
strated that a reduction in the duration of positive pres-
sure ventilation (of 1 week) [9] through an endotracheal
tube was associated with an improved rate of survival
without neuro-developmental disability (reduced rate of
cerebral palsy and cognitive delay) [10].
The Infant Flow™ System (Viasys Healthcare Inc, Yorba
Linda, CA, USA) used in our study is the most widely uti-
lized variable flow device. It uses high velocity jet flows
that can entrain gas on demand during inspiration and
therefore keep the CPAP level constant. On exhalation the
design of the nasal prongs results in some of the fresh gas
being shunted away through an expiratory outlet rather
than continuing to the nares reducing the expiratory work
[11-14]. In contrast to regular NCPAP which provides a
continuous distending pressure, biphasic NCPAP (BP-
NCPAP) cycles between upper and lower (baseline) level
pressures as determined by the following four parameters
a) lower CPAP level b) upper CPAP level c) time at upper
level and d) rate (cycles/minute at upper level). Theoreti-
cally, functional residual capacity is recruited by the upper
CPAP level and maintained with the lower baseline CPAP
level, thus decreasing the work of breathing. To date there
have been no studies comparing the use of these two
modes of non-invasive ventilation in preterm infants to
facilitate sustained extubation following an initial period of
intubation and positive pressure ventilation at birth.
The primary goal of this study was to compare the effec-
tiveness of BP-NCPAP vs. NCPAP using the Infant Flow®
SiPAP™ Viasys Healthcare Inc. system in facilitating sus-
tained extubation in preterm infants ≤ 1,250 grams. The
secondary goals were to compare the adverse events and
short-term neonatal morbidities between the two groups.
Methods
In this randomized controlled trial we included intubated
infants with birth weight ≤ 1,250 grams. Infants with con-
genital abnormalities of the upper airway tract, acquired
nasal septum injury and major congenital or chromosomal
abnormalities were excluded. The study was conducted at
a tertiary care NICU, Mount Sinai Hospital, Toronto,
Ontario, Canada, during the period from April 2006 to
November 2008.
Parents of eligible infants were approached for participa-
tion in the trial and written informed consent was
obtained prior to extubation. A marker was then placed at
the bedside of eligible infants whose parents had given
consent. Randomization cards were generated using a
computer generated random numbers list. The cards were
sealed in sequentially marked opaque envelopes and
opened immediately prior to the first extubation. Infants
were randomized to one of two groups: BP-NCPAP or
NCPAP delivered by the Infant Flow® SiPAP™ (Viasys
Healthcare, Yorba Linda, CA, USA). The assigned mode
of support was continued until the infant was ready to be
placed in room air or supplemental oxygen. The study was
approved by the local Research Ethics Board.
Preset criteria were used to guide extubation using a
consensus approach amongst neonatologists in our NICU.
For conventional ventilation the criteria included: a venti-
lator rate of < 20 breaths per minute (bpm), peak inspira-
tory pressure (PIP) ≤ 16 cm H2O and fractional inspired
oxygen (FiO2) of ≤ 0.35. For high frequency ventilation the
criteria were: frequency of 9-13 Hz, amplitude < 20 per-
cent, mean airway pressure (MAP) of ≤ 8 cm H2O and
FiO2 ≤ 0.35. Once an infant reached these preset criteria,
the medical team was approached for consideration of
extubation. In the event of accidental extubation in eligible
consented infants, face mask CPAP was applied for no
more than 15 minutes until a decision was made either to
reintubate based on the clinical condition or to randomize
to the study group. All infants had the appropriate bonnet,
nasal prong interface and Cannulaide® (Beevers Manufac-
turing Inc., McMinnville, OR, USA) applied.
In the BP-NCPAP arm the respiratory rate was set at
20 bpm with an inspiratory time of 1.0 second. The
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upper level of CPAP was set 3 cm above the lower
(baseline) level of CPAP. In both modes the lowest base-
line CPAP was set at 5 cm H2O and the CPAP was
titrated according to the infant’s FiO2 needs based on
an algorithm (Table 1). Neither mode of NCPAP was
synchronised with the infant’s respiratory effort. Wean-
ing in both groups was left at the discretion of the
attending neonatologist. If the infant remained clinically
stable in FiO2 ≤ 0.25 with no evidence of increased
work of breathing and/or apnea of prematurity, then
attempt was made to trial off CPAP.
Criteria for reintubation included: presence of severe
apnea (defined as need for positive pressure ventilation),
≥ 4 minor apneic episodes per hour requiring moderate
stimulation, required supplemental oxygen of > 60% to
maintain oxygen saturation > 88%, developed uncompen-
sated respiratory acidosis (defined a pH < 7.25) or a com-
bination of the above. Apnea was defined as cessation of
respiration for > 20 seconds or a shorter pause if asso-
ciated with bradycardia (heart rate < 100 beats per minute)
or desaturation (< 85%). Reintubation was also allowed at
the discretion of the attending medical team for other rea-
sons, e.g., concerns regarding sepsis. Data were collected
for the duration of their in-hospital stay. Other medical
therapy and interventions were provided at the discretion
of the medical team.
In our unit, caffeine is usually commenced in the first
week of life even if the infant requires positive pressure
ventilation via endotracheal tube. A loading dose of
10 mg/kg followed by maintenance dose of 2.5 mg/kg is
administered within 24-36 hours. Based on the clinical
response the maximum dose of maintenance caffeine used
is 5 mg/kg.
Data were collected on maternal characteristics includ-
ing age, gravidity, parity, pregnancy induced hyperten-
sion, essential hypertension, preterm prolonged rupture
of the membranes (> 18 hours), antenatal steroids (com-
plete and partial course), and clinical and histological
diagnosis of chorioamnionitis from maternal health
records and placental pathology.
The primary outcome was the incidence of sustained
extubation for 7 days. Secondary outcomes included inci-
dence of adverse events such as: nasal septal injury/
erythema, eyelid edema, abdominal distension, feeding
intolerance and pneumothorax. Nasal septal injury/
erythema and eyelid edema were monitored and recorded
every 4 hours by the respiratory therapists and the nursing
staff. Data on feeding intolerance (defined as aspirates of ≥
30% of a single feed administered) and abdominal disten-
sion (defined as > 10% increase in abdominal girth) were
recorded by the nursing staff every 4 hours and/or
prompted by clinical concerns. Data on the other clinical
outcomes including the incidence of BPD [oxygen depen-
dency at 36 weeks post menstrual age (PMA)], patent duc-
tus arteriosus (PDA) (diagnosed clinically or by ECHO and
treated with indomethacin ± surgery), necrotizing entero-
colitis (NEC) (Bell’s stage 2 or greater) [15], grade 3/4
intraventricular hemorrhage (IVH) [16] or periventricular
leucomalacia (PVL) and retinopathy of prematurity (ROP)
were abstracted from the chart. Retinopathy of prematur-
ity was classified according to the international classifica-
tion [17]. Infants who died were excluded from the
analysis for ROP and for BPD if they died before they
reached 36 weeks PMA. In our unit, PDA is treated phar-
macologically (with indomethacin) based on the presence
of clinical symptoms and signs. Prior to administration of
a second course of indomethacin or referral for surgical
ligation, infants undergo echocardiography. Both care-
givers administering the interventions and research assis-
tants were not blinded to the group assignment.
The sample size calculation was based on the results
obtained from a previous study that compared the rate of
sustained extubation using NCPAP vs. high flow oxygen
in our unit. The rate of sustained extubation with NCPAP
was 85% [18]. To demonstrate a clinically significant
increase in the rate of sustained extubation by 10%
between groups (i.e. from 85% to 93.5%) with 80% power
and an alpha value of 0.05, we estimated a sample size of
141 patients in each arm for a total of 282 patients.
The analysis was performed using the intention-to-treat
principle. Baseline maternal and infant characteristics and
outcomes of the infants randomized to both modes were
compared using c2 test for categorical data and Student’s t
test for continuous data. The Wilcoxon rank sum test was
used to compare continuous data with highly skewed dis-
tributions. All reported P values are two sided. A planned
secondary analysis examined the predictors of successful
extubation using multivariate logistic regression to control
for possible confounders including birth weight, sex, age
at the time of first extubation, accidental extubation and
use of antenatal steroids. All statistical analyses were per-
formed using the computer program Statistical Package
for the Social Sciences v.12™ (Chicago, IL, USA).
A P value of 0.05 was considered significant.
Table 1 Guidelines for use of biphasic nasal continuous
positive airway pressure (BP-NCPAP) and nasal
continuous positive airway pressure (NCPAP)











*FiO2 = Fraction of inspired oxygen
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Results
Of the 534 infants ≤ 1,250 grams admitted to the NICU
during the study period, 348 infants were eligible for the
study. Parents of 190 infants were approached of whom
43 declined and 147 consented. Four infants died and 7
were transferred to another site prior to randomization.
Thus, a total of 136 neonates were enrolled (Figure 1).
The trial had to be stopped prematurely prior to enrol-
ment of the intended sample size due to a change in
clinical practice in our unit that resulted in fewer infants
being intubated from birth. Results are presented for the
recruited subjects. No interim analysis was performed.
The demographic characteristics (birth weight, gesta-
tional age and sex) did not differ between participants
and non-participants. Sixty-seven infants were rando-
mized to BP-NCPAP and 69 to NCPAP. Baseline
maternal and neonatal characteristics of the participants
are presented in Tables 2 and 3, respectively. There
were no significant differences between the two groups.
The incidence of sustained extubation following the
first extubation was 67% (45/67) in the BP-NCPAP
group compared with 58% (40/69) in the NCPAP group
(P = 0.27). The reasons and time for reintubation in the
first 7 days following extubation are presented in Table
4. The incidence of adverse events and short-term neo-
natal outcomes were similar between groups except for
ROP which was higher in the BP-NCPAP group (P =
0.02) (Table 5). No infant developed pneumothorax fol-
lowing extubation with either mode.
Multivariate regression analysis identified that birth
weight was the most important predictor of sustained
















Figure 1 Flow diagram of study participants.
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used (Table 6). For every 100 grams increase in birth
weight the odds of a successful outcome was 1.49 times
higher.
Discussion
In our study, we were unable to demonstrate the effec-
tiveness of BP-NCPAP in facilitating sustained extuba-
tion. Further, the incidence of adverse events, reasons
for reintubation and short-term neonatal morbidities
except for ROP were similar in both groups. There may
be several reasons for our inability to show a difference
in the primary outcome. Firstly, we were unable to
recruit the predetermined sample size to demonstrate a
difference due to increasing use of non-invasive ventila-
tion from birth. This is a major flaw of our study. Sec-
ondly, the overall rate of sustained extubation in our






Maternal age (years) [Mean (SD)] 31.5 (6.3) 30.8 (5.9) 0.55
Gravida [Median (IQR)] 2 (1, 3) 2 (1, 3) 0.89
Parity [Median (IQR)] 0 (0, 1) 0 (0, 1) 0.97
Pregnancy induced hypertension/eclampsia [N (%)] 13 (21%) 17 (26%) 0.46
Essential hypertension [N (%)] 8 (13%) 8 (12%) 0.89
Prolonged rupture of membranes [N (%)] 20 (32%) 25 (38%) 0.42
Chorioamnionitis [N (%)]
Clinical 9 (14%) 15 (23%) 0.20
Histological 29 (52%) 26 (43%) 0.32
Antenatal steroid [N (%)]
Complete course 42 (67%) 47 (72%) 0.35
Partial course 11 (17%) 13 (20%)
None 10 (16%) 5 (8%)
*IQR = Inter-quartile range, N = Number, % = Percent, SD = Standard deviation






Gestational age (weeks) [Mean (SD)] 27.3 ± 1.9 27.4 ± 1.7 0.60
Birth weight (grams) [Mean (SD)] 901 ± 200 896 ± 156 0.86
Male [N (%)] 39 (58%) 31 (44%) 0.13
Apgar score (1 minute) [Median (IQR)] 5 (3, 7) 5 (2, 7) 0.56
Apgar score (5 minutes) [Median (IQR)] 8 (7, 9) 8 (7, 9) 0.63
Mode of ventilation [N (%)]
IPPV 50 (75%) 51 (74%) 0.85
HFOV 14 (21%) 16 (23%)
HFJV 3 (4%) 2 (3%)
Age at first extubation (days) [Median (IQR)] 3 (1-67) 3 (1-62) 0.85
Time of blood gas prior to extubation (hours) [Median (IQR)] 9 (5, 14) 7 (5, 12) 0.15
Blood gas prior to extubation [Mean (SD)]
pH 7.3 ± 0.1 7.3 ± 0.1 0.12
PCO2 47.1 ± 11.0 48.5 ± 10.9 0.48
FiO2 [Mean (SD)] 0.24 ± 0.06 0.26 ± 0.08 0.40
Fulfilled preset extubation criteria [N (%)] 47 (70%) 55 (80%) 0.20
Accidental extubation in infants who did not meet preset extubation criteria [N (%)] 6 (9%) 7 (10%) 0.98
Surfactant administration [N (%)] 61 (91%) 66 (96%) 0.32
Caffeine administration [N (%)] 65 (97%) 64 (92%) 0.44
*FiO2 = Fraction of inspired oxygen, HFJV = High frequency jet ventilation, HFOV = High frequency oscillatory ventilation, IPPV = Intermittent positive pressure
ventilation, IQR = Inter-quartile range, N = Number, % = Percent, SD = Standard deviation
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infants was much lower than anticipated. The rate of
sustained extubation in our study ranged from 58% to
67% compared to a rate of 85% used to determine our
sample size. Using these revised rates of sustained extu-
bation and an effect size of 10%, we would need to
recruit a total of 870 infants to demonstrate a difference.
Obviously conducting such a trial requires a collabora-
tive effort and is a major undertaking.
Our a priori hypothesis was to demonstrate/achieve a
clinically significant increase in the rate of sustained
extubation of 10% with the use of BP-NCPAP. With our
limited sample size we were able to demonstrate an
increase in the rate of sustained extubation by 9% in the
BP-NCPAP group even though this difference was not
statistically significant. We cannot rule out the possibility
that if we had indeed achieved our targeted sample size
we may have been able shown a statistically significant
difference. In clinical practice, this difference of 9% may
be considered clinically significant as there is increasing
trend of using non-invasive ventilation to avoid the con-
sequences of mechanical ventilation.
To our knowledge, there are no previous published stu-
dies that have evaluated BP-NCPAP for facilitating suc-
cessful sustained extubation following intubation and
ventilation at birth, i.e., used as a secondary mode. The
trial was initiated at our site when infants ≤ 1,250 grams
were routinely intubated and ventilated at birth and
administered prophylactic surfactant if ≤ 27 weeks gesta-
tion. Biphasic-NCPAP is considered a form of nasal
intermittent positive pressure ventilation (NIPPV) and






Successful extubation [N (%)] 45 (67%) 40 (58%) 0.27
Time of blood gas after extubation (hours) [Median (IQR)] 4 (2, 6) 2 (2, 4) 0.02
Blood gas after extubation [Mean (SD)]
pH 7.4 ± 0.1 7.3 ± 0.1 0.02
PCO2 45.8 ± 13.4 47.8 ± 13.3 0.39
FiO2 [Mean (SD)] 0.27 ± 0.09 0.26 ± 0.06 0.30
Time to reintubation (days) [Median (IQR)] 2 (1, 4) 1 (1, 5) 0.76
Number and reasons for reintubation [N (%)] N = 22 N = 29
Hypercapnia 0 0
FiO2 requirements > 60% 2 (9%) 0 0.14
Severe apnea defined as need for positive pressureventilation or frequent apnea defined as ≥ 4 minor
apneic episodes per hour requiring moderate stimulation
13 (59%) 23 (79%)
Combination of the above 7 (32%) 6 (21%)
*FiO2 = Fraction of inspired oxygen, IQR = Inter-quartile range, N = Number, % = Percent, SD = Standard deviation







Nasal septum breakdown [N (%)] 6 (8.9%) 9 (13%) 0.59
Eyelid edema [N (%)] 3 (4.5%) 2 (2.8%) 0.68
Feeding intolerance [N (%)] 8 (11.9%) 17 (25%) 0.08
Abdominal distension [N (%)] 16 (23.8%) 8 (12%) 0.07
Pneumothorax [N (%)] 0 0
Short-term neonatal outcomes
Mortality [N (%)] 3 (4%) 5 (7%) 0.49
New-onset sepsis after extubation [N (%)] 8 (12%) 5 (7%) 0.35
Bronchopulmonary dysplasia (oxygen dependency at 36 weeks PMA) [N (%)] 21 (31.3%) 22 (31.8%) 1.0
Necrotising enterocolitis [N (%)] 7 (10.4%) 7 (10.1%) 0.95
Grade 3/4 IVH/PVL 1/62 (1.6%) 5/65(7.7%) 0.41
ROP > stage 2 [N (%)] 11 (17%) 3 (5%) 0.02
Patent ductus arteriosus [N (%)] 36 (53.7%) 35 (51%) 0.82
*IVH = Intraventricular hemorrhage, N = Number, % = Percent, PVL = Periventricular leucomalacia, ROP = Retinopathy of prematurity
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therefore we compared the results of our study to those
of NIPPV when used as a secondary mode. In an updated
Cochrane review in 2008, Davis et al. [19] compared
NIPPV vs. CPAP for preterm infants after extubation.
They demonstrated a reduction in extubation failure rate
[relative risk (RR) 0.39; 95% confidence interval (CI) 0.16,
0.97)] with the use of synchronized NIPPV (data from 3
trials with N = 159) and concluded that it may potentially
be a way of augmenting NCPAP when used to prevent
extubation failure. Further evidence that NIPPV facili-
tates successful extubation comes from a recent rando-
mized controlled trial by Moretti et al. [20] in which 94%
(30/32) of infants in the NIPPV group were successfully
extubated (defined as no reintubation within 3 days)
compared with 61% (19/31) in the NCPAP group (P =
0.01). The details of the 4 published trials on NIPPV are
presented in Table 7.
The above findings are in contrast to the results of
our study. Possible explanations for the difference in the
effectiveness of NIPPV compared to BP-NCPAP include
variations in the: 1) definition of sustained extubation,
2) the median age of extubation and 3) ventilatory para-
meters used to prevent reintubation. The duration of
successful extubation in the NIPPV trials was defined as
48 hours [21] to 72 hours [20,22,23] vs. 7 days in our
study. Further, the median age of extubation was day 3
in our study vs. 7 days [22,23] and 18.5-21 days [21] in
the NIPPV studies. This later age of extubation may
have resulted in resolution of co-morbidities such as a
clinically significant patent ductus arteriosus in the first
7-10 days, which could contribute to successful sus-
tained extubation.
As BP-NCPAP is considered to be a form of NIPPV,
we conducted a meta-analysis including data from the 4
published studies and our results (Figure 2). The inci-
dence of extubation failure was lower with the use of
NIPPV and BP-NCPAP compared to NCPAP [Relative
risk (RR), 0.27; 95% confidence interval (CI), 0.17, 0.43;
P < 0.01]. No significant statistical heterogeneity was
noted for this outcome. The risk difference was -0.30,
95% CI (-0.38, -0.21; P < 0.01). The number needed to
prevent one infant from being reintubated was 3 (95%
CI, 2, 5).
When we designed our study, there were no previous
studies to guide us in our choice of ventilatory para-
meters to be used to provide effective BP-NCPAP. The
maximum upper level of CPAP that can be set with BP-
NCPAP is less than that used for NIPPV and with the
use of endotracheal tube and ventilation. In our study,
the upper level of CPAP varied from 8 to 10 cmH2O
Table 6 Predictors of successful extubation




Mode of CPAP 1.51 (0.71, 3.20) 0.28
Birth weight in increments of 100
grams
1.49 (1.11, 1.82) 0.003
Female 1.84 (0.87, 3.92) 0.11
Antenatal steroids 1.01 (0.98, 1.05) 0.47
Age at time of first extubation 0.31 (0.08, 1.32) 0.11
Accidental extubation 0.81 (0.30, 2.14) 0.67
* CPAP = Continuous positive airway pressure, CI = Confidence interval
Table 7 Review of the literature on nasal intermittent positive pressure ventilation (NIPPV) vs. nasal continuous



















Extubation failure at 72
hours
4/27 (14%) vs. 12/27 (44%) in the NSIMV vs. NCPAP
(P < 0.05)
Median age at extubation (range)
3 (1, 29) vs. 3 (1, 40) days








1/22 (5%) vs.7/19 (37%) in the NP-SIMV vs. NCPAP
group
(P = 0.016)
Median age at extubation (range) 18.5 (1, 120) vs.
21(1, 54) days






Remained extubated at 72
hours
32/34 (94%) vs. 18/30 (60%) in the SNIPPV vs.
NCPAP group
(P < 0.01)











Remained extubated at 72
hours
30/32 (94%) vs. 19/31(61%) in the
NFSIPPV vs. NCPAP (P < 0.01)
Median age at extubation (range)
4 (1, 14) vs. 6 (1, 14) days
*BW = Birth weight, CPAP = Continuous positive airway pressure, GA = Gestational age, NCPAP = Nasal continuous positive airway pressure, NSIMV = Nasal
synchronized intermittent mandatory ventilation, NFSIPPV = Nasal flow synchronized intermittent positive pressure ventilation, PNA = Post natal age, SNIPPV =
Synchronized nasal intermittent positive pressure ventilation
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based on the oxygen requirements of the infant. The
inspiratory and expiratory time were set at 1.0 and
2.0 seconds respectively resulting in a pressure exchange
rate of 20 breaths per minute (cycle/minute at upper
level). We were unable to synchronize the delivery of
the upper level of CPAP with this device. The combina-
tion of lack of synchronization with low pressure
exchange rate and upper level of CPAP may have been
critical factors contributing to our failure in facilitating
sustained extubation. With most modes of NCPAP or
indeed NIPPV synchronisation is imperfect, using either
a Graseby capsule on the infant’s abdomen or most
recently a flow detector at the nares [24]. When a
higher rate of ventilation is used as in most modes of
NIPPV then synchronisation happens more often just by
chance. Synchronisation may be important for entrain-
ment of tidal volumes both on inspiration and expira-
tion [24-26] and that this may in part explain the
clinical benefit of synchronised NIPPV.
Recently, BP-NCPAP has been evaluated for infants with
moderate respiratory distress syndrome as a primary mode
of ventilation. Infants between 28-34 weeks gestation were
randomized to either BP-NCPAP or NCPAP in the first
hour of birth. The use of BP-NCPAP was associated with
shorter respiratory support and oxygen dependency with
no difference in the rate of reintubation [27]. In the BP-
NCPAP group; the investigators used a pressure exchange
rate of 30 bpm, inspiratory time of 0.5-0.7 seconds and
upper and lower CPAP level of 8 and 4.5 cm H2O
respectively.
Adverse events such as increased risk of pneu-
mothorax, nasal septal trauma, feeding intolerance,
abdominal distension and gram-negative sepsis secondary
to nasal mucosal barrier breakdown have been described
in the literature with the use of various forms of NCPAP
[5,28,29]. The incidence of pneumothorax was reported
to be 6.8% [5] and 9% [29] respectively in the Support
and the COIN trial where NCPAP was used soon after
birth. We did not find any increase in the risk of pneu-
mothorax in our trial. One major difference between the
previous studies and ours is that we used NCPAP after
the first extubation rather than using it as a primary
mode of ventilation. Increased risk of gastric perforation
has been reported with the use of NIPPV [30]. No differ-
ences in the rate of short-term neonatal morbidities,
especially BPD were noted between groups in our study.
We did find an increased risk of ROP in the BP-NCPAP
compared to NCPAP group (P = 0.02). It is important to
recognize that our study was not powered to detect dif-
ferences in these secondary outcomes so the finding of
increased incidence of ROP needs to be confirmed/
refuted in future studies.
Conclusion
BP-NCPAP may be used safely and effectively to assist
in weaning from mechanical ventilation. However, the
effectiveness and safety of BP-NCPAP compared to
NCPAP needs to be confirmed in a large multi-center
trial as our study conclusions are limited by inadequate
sample size.
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